Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial)

Intraperitoneal and intravenous paclitaxel plus S-1 and sintilimab as frst-line treatment for gastric cancer with peritoneal metastasis:asingle-arm phase 2 trial (DRAGON-09)

On-treatment bloodTMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phasel trial

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase l trials

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma

Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer

Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers

The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage lB-llB non-small cell lung cancer: biomarker analyses from a prospective phase ll trial

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study

TOTEM: a multi-cancer detection and localization approach using circulating tumor DNA methylation markers

Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection

P3.06D.01 Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Treatment-Naive Patients with Advanced Lung Squamous Cancer